Abstract:Co-infection between HIV-1 and HCV is common today in certain populations. However, treatment of co-infection is full of challenges with special consideration for potential hepatic safety and drug-drug interactions. Multitarget inhibitors with less toxicity may provide a promising therapeutic strategy for HIV/HCV co-infection. However, identification of one molecule acting on multiple targets simultaneously by experimental evaluation is costly and time-consuming. In silico target prediction tools provide more opportunities for the development of multitarget inhibitors. In this study, by combining naive Bayesian (NB) and support vector machine (SVM) algorithms with two types of molecular fingerprints (MACCS and ECFP6), 60 classification models were constructed to predict the active compounds toward 11 HIV-1 targets and 4 HCV targets based on the multitarget-quantitative structure-activity relationships (mt-QSAR). 5-fold cross-validation and test set validation was performed to confirm the performance of 60 classification models. Our results show that 60 mt-QSAR models appeared to have high classification accuracy in terms of ROC-AUC values ranging from 0.83 to 1 with a mean value of 0.97 for HIV-1 models, and ROC-AUC values ranging from 0.84 to 1 with a mean value of 0.96 for HCV. Furthermore, the 60 models were applied to comprehensively predict the potential targets for additional 46 compounds including 27 approved HIV-1 drugs, 10 approved HCV drugs and 9 selected compounds known to be active on one or more targets of HIV-1 or those of HCV. Finally, 18 hits including 7 HIV-1 approved drugs, 4 HCV approved drugs and 7 compounds were predicted to be HIV/HCV co-infection multitarget inhibitors. The reported bioactivity data confirmed that 7 compounds actually interacted with HIV-1 and HCV targets simultaneously with diverse binding affinities. Of those remaining predicted hits and chemical-protein interaction pairs involving the potential ability to suppress HIV/HCV co-infection deserve further investigation by experiments. This investigation shows that the mt-QSAR method is available to predict chemical-protein interaction for discovering multitarget inhibitors and provide a unique perspective on HIV/HCV co-infection treatment.

Quantitative Structure Activity Relationship (qsar) Approach to Multiple Drug Resistance (mdr) Modulators Based on Combined Hybrid System

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Prediction of the Aquatic Toxicity of Aromatic Compounds to Tetrahymena Pyriformis Through Support Vector Regression

Multi-task learning models for predicting active compounds

Comparative Study of Qsar/Qspr Correlations Using Support Vector Machines, Radial Basis Function Neural Networks, and Multiple Linear Regression

Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models

QSAR Study of Malonyl-Coa Decarboxylase Inhibitors Using GA-MLR and a New Strategy of Consensus Modeling.

A Linear and Nonlinear QSAR Analysis of Benzimidazole Derivative XY123 in Prostate Cancer Treatment

Prediction of bioactivities of microsomal prostaglandin E2 synthase-1 inhibitors by machine learning algorithms

QSAR Models for 2-Amino-6-arylsulfonylbenzonitriles and Congeners HIV-1 Reverse Transcriptase Inhibitors Based on Linear and Nonlinear Regression Methods.

Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery

In Silico Pharmacophore Models to Predict Endogenous Substrates for Human Multidrug Resistance-Associated Proteins

Support Vector Machine and Pharmacophore-Based Prediction Models of Multidrug-Resistance Protein 2 (mrp2) Inhibitors

Combined Qsar and Molecule Docking Studies on Predicting P-Glycoprotein Inhibitors

A breast cancer-specific combinational QSAR model development using machine learning and deep learning approaches

QSAR and Classification Models of a Novel Series of COX-2 Selective Inhibitors: 1, 5-Diarylimidazoles Based on Support Vector Machines

Centralized data sources and QSAR methods for the prediction of idiosyncratic adverse drug reaction

Regression Methods For Developing Qsar And Qspr Models To Predict Compounds Of Specific Pharmacodynamic, Pharmacokinetic And Toxicological Properties

ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning

Targeting against HIV/HCV Co-infection using Machine Learning-based multitarget-quantitative structure-activity relationships (mt-QSAR) Methods

QSAR Modelling Study of the Bioconcentration Factor and Toxicity of Organic Compounds to Aquatic Organisms Using Machine Learning and Ensemble Methods.